Cantor Fitzgerald analyst Louise Chen says Theravance Biopharma has many catalysts in 2020 and beyond to drive the stock higher. As a result, now is a good time to take another look at a stock that is "well capitalized, undervalued and underappreciated," Chen tells investors in a research note. Theravance successfully executed on its stated business objectives in 2019, setting it up for strong momentum into 2020 as it continues to expand on the commercial launches of Trelegy Ellipta and Yupelri as well as advance its "best-in-class pipeline," contends the analyst. She keeps an Overweight rating on the shares with a $55 price target.